IMPACT OF MIRABEGRON TREATMENT AND SYMPTOM SEVERITY ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH OVERACTIVE BLADDER

被引：1
|
作者：
De, G. [1 ]
Yang, H. [2 ]
Runken, M. C. [3 ]
Yan, Y. [1 ]
Kelkar, S. [1 ]
Bui, C. N. [3 ]
Xie, J. [1 ]
Wu, E. Q. [2 ]
机构：
[1] Anal Grp Inc, New York, NY USA
[2] Anal Grp Inc, Boston, MA USA
[3] Astellas Pharma US Inc, Northbrook, IL USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.923
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A183 / A184
页数：2
相关论文
共 50 条
  • [41] THE RISK AND SEVERITY OF DEVELOPING SYMPTOMATIC PALPITATIONS WHEN PRESCRIBED MIRABEGRON FOR OVERACTIVE BLADDER
    Balachandran, A.
    Duckett, J.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2015, 26 : S37 - S38
  • [42] Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?
    Marcelissen, Tom A. T.
    Van Koeveringe, Gommert A.
    EUROPEAN UROLOGY, 2018, 74 (03) : 334 - 335
  • [43] The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder
    Balachandran, Aswini A.
    Duckett, Jonathan R. A.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 187 : 60 - 63
  • [44] Work productivity in patients with overactive bladder: Results from the MATRIX study
    Talati, AR
    Pizzi, LT
    Dahl, N
    Gemmen, E
    VALUE IN HEALTH, 2006, 9 (03) : A99 - A99
  • [45] Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?
    Manami Kinjo
    Kazuki Masuda
    Yu Nakamura
    Satoru Taguchi
    Mitsuhiro Tambo
    Hiroshi Fukuhara
    International Urogynecology Journal, 2023, 34 : 853 - 859
  • [46] Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?
    Kinjo, Manami
    Masuda, Kazuki
    Nakamura, Yu
    Taguchi, Satoru
    Tambo, Mitsuhiro
    Fukuhara, Hiroshi
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2023, 34 (04) : 853 - 859
  • [47] MIRABEGRON® FOR THE TREATMENT OF OVERACTIVE BLADDER IN NAVE PATIENTS: REAL LIFE DATA IN AN ITALIAN SETTING
    Fuse, Federica
    Casati, Patrizia
    Soligo, Marco
    Casati, Daniela
    Scebba, Ileana
    Montecorboli, Giulia
    Stellio, Leonardo Nelva
    Ferrazzi, Enrico
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 : S36 - S37
  • [48] Impact of overactive bladder symptoms on work activity: The ACTIVHA study
    Rapariz, M.
    Mora, A. M.
    Roset, M.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (03): : 176 - 184
  • [49] The overactive bladder-symptom composite score: A composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder
    Zinner, N
    Harnett, M
    Sabounjian, L
    Sandage, B
    Dmochowski, R
    Staskin, D
    JOURNAL OF UROLOGY, 2005, 173 (05): : 1639 - 1643
  • [50] New data on the combined treatment of solifenacin and mirabegron in patients with overactive bladder: SYNERGY study
    Alcantara Montero, A.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (01): : 70 - 71
12345